The MSOS cannabis ETF hit a 2026 high ahead of the DEA's July 15 rescheduling deadline, as Trulieve, Curaleaf and Canopy Growth reshape the sector.

One ETF promises to hand cautious investors a clean shot at the U.S. cannabis trade without the chaos of OTC accounts and ...

The DEA's cannabis rescheduling hearing runs through a July 15 deadline, putting cannabis stocks and the MSOS ETF in focus.

The cannabis ETF has surged 104% over the past year, outperforming both the North American Marijuana Index and the S&P 500.

In which of these cannabis stocks should investors plant their money?

U.S. reform of federal medical marijuana laws is giving a boost to cannabis stocks, and there appears to be more upside potential as the government also considers reclassifying recreational marijuana ...

It may not be the American Dream per se, but the universe of cannabis exchange-traded funds got much more American Wednesday with the debut of the AdvisorShares Pure US Cannabis ETF (NYSE: MSOS). What ...

Investors in Advisorshares Trust Advisorshares Pure US Cannabis (Symbol: MSOS) saw new options begin trading today, for the February 25th expiration. At Stock Options Channel, our YieldBoost formula ...

Investors in Advisorshares Trust Advisorshares Pure US Cannabis (Symbol: MSOS) saw new options become available today, for the February 2026 expiration. One of the key inputs that goes into the price ...

Will the rescheduling of cannabis fuel a boom in cannabis stocks? Analysts from Z&A delve into the pros and cons of MSOs and cannabis rescheduling in their latest equity research report. Re-scheduling ...